Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Debt Repayments (2022 - 2023)

Arcturus Therapeutics Holdings (ARCT) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $20.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Debt Repayments rose 566.67% year-over-year to $20.0 million, compared with a TTM value of $20.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $15.0 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $20.0 million for Q4 2023 at Arcturus Therapeutics Holdings, down from $27.4 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $27.4 million in Q1 2023 and bottomed at $3.0 million in Q4 2022.